Pantziarka P - Search Results

1

How to develop new systemic treatments in ultra-rare cancers with high unmet needs? The case of alveolar soft-part sarcoma.

Stacchiotti S, Bouche G, Herold R, Pantziarka P, Schuster K, Wilson R, Pignatti F, Kasper B. Stacchiotti S, et al. Among authors: pantziarka p. Eur J Cancer. 2024 May;202:114003. doi: 10.1016/j.ejca.2024.114003. Epub 2024 Mar 11. Eur J Cancer. 2024. PMID: 38479120

2

The patient perspective on sirolimus for epithelioid hemangioendothelioma (EHE): results of a community survey highlighting the importance of equitable access to treatments.

Robinson D, Leonard H, Baldi GG, Tap WD, Jones RL, Stacchiotti S, Pantziarka P. Robinson D, et al. Among authors: pantziarka p. Front Oncol. 2024 Feb 26;14:1367237. doi: 10.3389/fonc.2024.1367237. eCollection 2024. Front Oncol. 2024. PMID: 38469238 Free PMC article.

3

Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol.

Dixon-Zegeye M, Shaw R, Collins L, Perez-Smith K, Ooms A, Qiao M, Pantziarka P, Izatt L, Tischkowitz M, Harrison RE, George A, Woodward ER, Lord S, Hawkes L, Evans DG, Franklin J, Hanson H, Blagden SP. Dixon-Zegeye M, et al. Among authors: pantziarka p. Trials. 2024 Feb 3;25(1):103. doi: 10.1186/s13063-024-07929-w. Trials. 2024. PMID: 38308321 Free PMC article.

4

Drug evidence watch: a process to the benefit of public health.

Pantziarka P, Roberts I, Vandamme P, Meheus L, Bouche G. Pantziarka P, et al. Lancet. 2023 Sep 16;402(10406):945-947. doi: 10.1016/S0140-6736(23)00633-5. Epub 2023 Apr 13. Lancet. 2023. PMID: 37060913 No abstract available.

5

Exploiting the Stemness and Chemoresistance Transcriptome of Ewing Sarcoma to Identify Candidate Therapeutic Targets and Drug-Repurposing Candidates.

Roundhill EA, Pantziarka P, Liddle DE, Shaw LA, Albadrani G, Burchill SA. Roundhill EA, et al. Among authors: pantziarka p. Cancers (Basel). 2023 Jan 26;15(3):769. doi: 10.3390/cancers15030769. Cancers (Basel). 2023. PMID: 36765727 Free PMC article.

6

Drug repurposing as a potential source of innovative therapies in cervical cancer.

Capistrano I R, Paul S, Boere I, Pantziarka P, Chopra S, Nout RA, Bouche G. Capistrano I R, et al. Among authors: pantziarka p. Int J Gynecol Cancer. 2022 Sep 22;32(11):1377-86. doi: 10.1136/ijgc-2022-003585. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 36137575 Free PMC article.

7

Drug Repurposing by Tumor Tissue Editing.

Lüke F, Harrer DC, Pantziarka P, Pukrop T, Ghibelli L, Gerner C, Reichle A, Heudobler D. Lüke F, et al. Among authors: pantziarka p. Front Oncol. 2022 Jun 24;12:900985. doi: 10.3389/fonc.2022.900985. eCollection 2022. Front Oncol. 2022. PMID: 35814409 Free PMC article. Review.

8

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.

Pantziarka P, Blagden S. Pantziarka P, et al. Cancers (Basel). 2022 Mar 23;14(7):1621. doi: 10.3390/cancers14071621. Cancers (Basel). 2022. PMID: 35406393 Free PMC article. Review.

9

A Database of Drug Repurposing Clinical Trials in Oncology.

Pantziarka P, Vandeborne L, Bouche G. Pantziarka P, et al. Front Pharmacol. 2021 Nov 10;12:790952. doi: 10.3389/fphar.2021.790952. eCollection 2021. Front Pharmacol. 2021. PMID: 34867425 Free PMC article. No abstract available.

10

Use of non-cancer drugs and survival among patients with pancreatic adenocarcinoma: a nationwide registry-based study in Norway.

Støer NC, Bouche G, Pantziarka P, Sloan EK, Andreassen BK, Botteri E. Støer NC, et al. Among authors: pantziarka p. Acta Oncol. 2021 Sep;60(9):1146-1153. doi: 10.1080/0284186X.2021.1953136. Epub 2021 Aug 2. Acta Oncol. 2021. PMID: 34338111

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

50 results

Search Page